雌二醇周效贴片166例疗效观察

本研究观察国产雌二醇周效贴片（Ｅ２贴片）治疗因卵巢功能低落所致的主要临床表现的疗效，结合血ＦＳＨ、ＬＨ、Ｅ２测定，阴道脱落细胞成熟指数和部分病例的子宫内膜活检，对Ｅ２贴片的疗效进行了综合评价。结果显示，雌二醇周效贴片对卵巢功能低落所致的潮热、出汗、失眠、情绪波动，眩晕和阴道干涩等有显著疗效，且疗效随用药时间的延长而递增，在用药１４０天时总有效率分别达９８．９％，９２．０％、９１．４％、９０．０％和７８．０％，对ＬＨ、ＦＳＨ的释放有抑制作用；血清Ｅ２水平属轻度升高，但趋于平稳；部分病例子宫内膜组织学检查未见雌激素作用所致的内膜增殖效应。用药期间部分病例出现周期性阴道出血，这对年轻卵巢功能早哀者在生理和心理上均有治疗意义，但对更年期患者会造成不便和不安感。约２０％的病例贴片局部有轻微痒感，无其它不良反应。     

111例双黄连过敏反应文献分析

目的:分析临床应用双黄连引致的过敏反应的规律。方法:对2000年1月-2004年3月中国期刊网中收录的111例双黄连过敏反应在性别、年龄、发生时间、给药途径和临床表现进行分析。结果:双黄连过敏与年龄、性别无关,与给药途径有关,注射剂易发生过敏反应。该药过敏的临床表现有:过敏性休克67例(60%),皮肤黏膜症状61例(55%),其他类型过敏反应14例(13%)31例同时出现多种过敏症状。过敏发生时间最短为开始用药1m in以内,最长为用药后72h,97例(87%)在用药过程中发生过敏症状。结论:双黄连的过敏反应以速发型过敏反应(如过敏性休克)为主,应是临床关注的重点。     

Reversal of ischemic liver failure by intrasplenic liver cell transplantation

A model of ischemic hepatic failure in Sprague-Dawley rats (SD) with 100% mortality has been developed by one-hour occlusion of the right portal vein and hepatic artery followed by left 70% hepatectomy. The intrasplenic injection of 40 x 10(6) syngeneic adult or three-day neonatal single liver cell suspensions decreased the mortality from 100% to 50% and 36%, respectively. Mortality decreased with increasing time from the intrasplenic injection of neonatal liver cells to the time of acute hepatic ischemia. Mortality also decreased with increasing interval between hepatic ischemia and removal of the transplanted liver cells by splenectomy. Intrasplenic injection of graded doses of neonatal liver cells decreased mortality from 75% at a dose of 10 x 10(6) cells, to 36% at 160 x 10(6) cells. Treatment of neonatal liver cells with metabolic inhibitors did not significantly affect their ability to reverse acute hepatic ischemia.     

Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease

Previously, we reported that short term administration of a highly potent GnRH agonist (GnRHa) for 1 month to patients with polycystic ovarian disease (PCO) resulted in complete suppression of ovarian steroidogenesis without measurable effects on adrenal steroid production. This new study was designed to evaluate the effects of long term GnRHa administration in PCO patients with respect to their hormone secretion patterns and clinical responses. Eight PCO patients and 10 ovulatory women with endometriosis were treated daily with sc injections of [D-His6-(imBzl]),Pro9-NEt]GnRH (GnRHa; 100 micrograms) for 6 months. Their results were compared to hormone values in 8 women who had undergone bilateral oophorectomies. In response to GnRHa, PCO and ovulatory women had rises of serum LH at 1 month, after which it gradually declined to baseline. In both groups FSH secretion was suppressed throughout treatment. Serum estradiol, estrone, progesterone, 17-hydroxyprogesterone, androstenedione, and testosterone levels markedly decreased to values found in oophorectomized women by 1 month and remained low thereafter. In contrast, serum pregnenolone and 17-hydroxypregnenolone were partially suppressed, and dehydroepiandrosterone, dehydroepiandrosterone sulfate, and cortisol levels did not change. Clinically, hyperplastic endometrial histology in three PCO patients reverted to an inactive pattern, and proliferative endometrium in two other PCO patients became inactive in one and did not change in the other. Regression of proliferative endometrial histology occurred in all ovulatory women. Vaginal bleeding occurred in all women studied during the first month of GnRHa administration, after which all but one PCO patient became amenorrheic. Hot flashes were noted by all ovulatory women and by four of eight PCO patients. All PCO patients noted subjective reduction of skin oiliness, and five had decreased hair growth. We conclude that in premenopausal women: 1) chronic GnRHa administration results in apparently complete persistent suppression of ovarian steroid secretion; 2) adrenal steroid secretion is not influenced directly or indirectly; and 3) its use may be helpful in the treatment of endometrial hyperplasia and ovarian androgen excess in women with PCO.     

精索静脉曲张患者精索静脉和外周血睾酮水平的对照研究

目的：探讨精索静脉血张患者血浆睾酮水平的变化及其机制。方法：对25例精索静脉曲张患者与22例腹股沟斜疝患者精索静脉和外周血睾酮水平进行对照研究。结果：精索静脉曲张组外周血睾酮浓度与腹股沟斜疝组无差别（P＞0．05），而精索静脉血睾酮浓度两组则有明显差异，精索静脉曲张组精索静脉血中睾酮浓度较腹股沟斜疝组低（P＜0．05）。结论：多种因素可影响外周血睾酮浓度，使其难以准确地反映睾丸分泌睾酮的实际水平，而精索静脉血中的睾酮浓度则能较为直接地反映睾丸的睾酮分泌能力。     

复方华蟾胶囊抗小鼠肿中瘤作用的实验研究

目的了解复方华蟾胶囊抗小鼠移植性肿瘤的作用.方法以小鼠肝癌22(H22)、小鼠肉瘤180(S180)为瘤株,应用动物移植性肿瘤的体内试验法对药物进行抗癌药效学试验.结果复方华蟾胶囊灌胃4,2 g/kg@d,连续14 d,对小鼠移植性肝癌实体型生长有明显的抑制作用,抑瘤率分别为38.09%,30.95%.对小鼠移植性S180实体型生长有明显的抑制作用,抑瘤率分别为34.7%,30.08%.复方华蟾胶囊对荷瘤小鼠的胸腺和脾脏重量无影响.结论复方华蟾胶囊在试验条件下有一定抗肿瘤作用.     

国产头孢三嗪在急性感染病人中的药代动力学

静脉滴注国产头孢三嗪0.5～1克,治疗8例急性感染病人的药代动力学。静注后半小时用HPLC测得的平均血药浓度为100.75μg/ml,24小时的血药浓度为11.4μg/ml,国产头孢三嗪的药代动力学特点与国外同类产品基本一致。半衰期长,清除半衰期为8.8小时,可在血液和感染部位中保持较长时间的杀菌和抑菌浓度,总表观分布容积为13.0L/kg,表明药物在组织中的浓度高。本品用量小,每日1克1～2次即可达到疗效。5例慢性胆囊炎伴胆石症患者静滴头孢三嗪1克后,2小时胆汁的平均药物浓度为1022.8μg/ml,可作为治疗胆道感染的有效药物。     

类保幼激素对三带喙库蚊幼期发育的影响

本文报告用亚致死剂量的 S—31183(类保幼激素)处理三带喙库蚊幼虫对其发育影响的研究,结果表明处理后蛹期死亡率明显高于幼虫期,并且与剂量大小有关。S—31183处理幼虫并不影响幼虫的发育时间,但可使幼虫化蛹时蜕皮受阻与羽化受到一定的抑制。     

X综合征的临床诊断与分析

目的；探讨临床医师对X综合征的临床诊断水平并了解其发病机制；方法：对186例有胸痛的女性患者（平均年龄53.2岁）通过运动试验，左室功能及冠状动脉造影来评估X综合征患者冠脉微循环功能及发病机制；结果：186例中86人（46％）冠脉造影阴性，运动试验阳性，左室功能无明显失调；结论：X综合征多见于女性，X综合征可能是由于冠脉微血管功能异常所致。